Results 31 to 40 of about 248,205 (145)

Another treatment option for relapsed or refractory chronic lymphocytic leukaemia. [PDF]

, 2017
We hereby report the clinical and biologic features of 33 of 4680 (0.7%) patients with chronic lymphocytic leukemia (CLL), managed at 10 Italian centers, who developed Hodgkin lymphoma (HL), a rare variant of Richter syndrome.
Mauro, Francesca Romana
core   +1 more source

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

New England Journal of Medicine, 2014
BACKGROUND Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy.
R. Furman, J. Sharman, S. Coutre, B. Cheson, J. Pagel, P. Hillmen, J. Barrientos, A. Zelenetz, T. Kipps, I. Flinn, P. Ghia, H. Eradat, T. Ervin, N. Lamanna, B. Coiffier, A. Pettitt, Shuo Ma, S. Stilgenbauer, P. Cramer, Maria Aiello, D. Johnson, L. Miller, Daniel Li, T. Jahn, R. Dansey, M. Hallek, S. O'brien   +26 more
semanticscholar   +1 more source

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

New England Journal of Medicine, 2015
BACKGROUND Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addition to disease-related immunosuppression and myelosuppression.
J. Burger, A. Tedeschi, P. Barr, T. Robak, C. Owen, P. Ghia, O. Bairey, P. Hillmen, N. Bartlett, Jianyong Li, D. Simpson, S. Grosicki, S. Devereux, H. McCarthy, S. Coutre, H. Quach, G. Gaidano, Z. Maslyak, D. Stevens, A. Janssens, F. Offner, J. Mayer, M. O'Dwyer, A. Hellmann, A. Schuh, T. Siddiqi, A. Polliack, C. Tam, Deepali Suri, M. Cheng, F. Clow, L. Styles, D. James, T. Kipps   +33 more
semanticscholar   +1 more source

T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?

Leukemia, 2020
Chronic lymphocytic leukemia (CLL) is a B-cell malignancy, which is associated with profound alterations and defects in the immune system and a prevalent dependency on the microenvironmental niche.
P. Roessner, M. Seiffert
semanticscholar   +1 more source

A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.

New England Journal of Medicine, 2005
BACKGROUND MicroRNA expression profiles can be used to distinguish normal B cells from malignant B cells in patients with chronic lymphocytic leukemia (CLL). We investigated whether microRNA profiles are associated with known prognostic factors in CLL.
G. Calin, M. Ferracin, A. Cimmino, Gianpiero di Leva, M. Shimizu, Sylwia E. Wojcik, M. Iorio, R. Visone, Nurettin Ilfer Sever, M. Fabbri, R. Iuliano, T. Palumbo, F. Pichiorri, C. Roldo, R. Garzon, C. Sevignani, L. Rassenti, H. Alder, S. Volinia, Chang-gong Liu, T. Kipps, M. Negrini, C. Croce   +22 more
semanticscholar   +1 more source

A Case of Hyperkalemia Versus Pseudohyperkalemia in Chronic Lymphocytic Leukemia [PDF]

, 2020
Introduction: Both hyperkalemia and pseudohyperkalemia occur in the emergency department. True hyperkalemia necessitates emergent treatment while pseudohyperkalemia requires recognition to prevent inappropriate treatment.
Geary, Sean P., Le, Rachel D.
core   +1 more source

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. [PDF]

, 2017
BackgroundThe CXCR4-CXCL12 axis plays an important role in the chronic lymphocytic leukemia (CLL)-microenvironment interaction. Overexpression of CXCR4 has been reported in different hematological malignancies including CLL.
Amaya-Chanaga, Carlos I, Amine, Ale-Ali, Castro, Januario E, Choi, Michael Y, Fantin, Valeria R, Gu, Yin, Hallin, Max, Huser, Nanni, Kashyap, Manoj K, Kipps, Thomas J, Kumar, Deepak, Lindquist, Kevin, Liu, Shu-Hui, Pernasetti, Flavia, Rassenti, Laura Z, Simmons, Brett, Smeal, Tod, Yafawi, Rolla, Zhang, Cathy   +18 more
core   +4 more sources

Multiple BCL2 mutations co-occurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.

Blood, 2020
The BCL2 inhibitor venetoclax has complete response rates of up to 50% in chronic lymphocytic leukemia patients, but secondary resistance reflecting acquired mutations in BCL2 can lead to treatment failure.
P. Blombery, E. Thompson, Tamia Nguyen, R. Birkinshaw, Jia-Nan Gong, Xiangting Chen, M. McBean, R. Thijssen, Thomas Conway, M. Anderson, J. Seymour, D. Westerman, P. Czabotar, D. Huang, A. Roberts   +14 more
semanticscholar   +1 more source

Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia. [PDF]

, 2014
Ofatumumab is a humanized anti-CD20 monoclonal antibody that has been approved by the FDA for the treatment of patients with chronic lymphocytic leukemia. We conducted a phase II single-arm study at a single center.
Almahasnah, E, Carvajal, T, Castro, JE, Chang, J, Choi, MY, James, DF, Kipps, TJ   +6 more
core   +3 more sources

Neutrophils in chronic lymphocytic leukemia are permanently activated and have functional defects [PDF]

, 2017
A growing body of studies highlights involvement of neutrophils in cancer development and progression. Our aim was to assess the phenotypic and functional properties of circulating neutrophils from patients with chronic lymphocytic leukemia (CLL).
Gabčová, Gabriela, Gajdoš, Petr, Kriegová, Eva, Kudělka, Miloš, Manukyan, Gayane, Mikulková, Zuzana, Papajík, Tomáš, Procházka, Vít, Ryznerová, Pavlína, Turcsányi, Peter, Urbanová, Renata   +10 more
core   +1 more source